Patents by Inventor Yonghua Gai

Yonghua Gai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oximyl HCV serine protease inhibitors
    Patent number: 8361958
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: December 4, 2008
    Date of Patent: January 29, 2013
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Quinoxaline-containing compounds as hepatitis C virus inhibitors
    Patent number: 8324155
    Abstract: The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 4, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Triazole-containing macrocyclic HCV serine protease inhibitors
    Patent number: 8273709
    Abstract: The present invention discloses compounds of formula I, II and III or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: September 25, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20120196792
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: April 4, 2012
    Publication date: August 2, 2012
    Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIES
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Ken Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
  • Macrocyclic oximyl hepatitis C serine protease inhibitors
    Patent number: 8222203
    Abstract: The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: December 12, 2008
    Date of Patent: July 17, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Ying Sun, Yonghua Gai, Yat Sun Or, Zhe Wang
  • Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors
    Patent number: 8211891
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: July 3, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Dong Liu, Joel D. Moore, Yat Sun Or, Zhe Wang
  • MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS
    Publication number: 20120101031
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: June 7, 2011
    Publication date: April 26, 2012
    Applicants: ENANTA PHARMACEUTICALS, INC., ABBOTT LABORATORIES
    Inventors: Hui-Ju Chen, Keith F. McDaniel, Brian E. Green, Jason P. Shanley, Albert W. Kruger, Jorge Gandarilla, Dennie S. Welch, Russell D. Cink, Steven C. Cullen, Yonghua Gai, Guoqiang Wang, Yat Sun Or
  • Heteroaryl-containing tripeptide HCV serine protease inhibitors
    Patent number: 8101567
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: January 22, 2009
    Date of Patent: January 24, 2012
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • BISMACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20110123496
    Abstract: The present invention discloses compounds of formula Ia or Ib or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: October 19, 2010
    Publication date: May 26, 2011
    Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
  • Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors
    Publication number: 20110105485
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Application
    Filed: July 21, 2010
    Publication date: May 5, 2011
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Quinoxalinyl dipeptide hepatitis C virus inhibitors
    Patent number: 7910587
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: April 24, 2008
    Date of Patent: March 22, 2011
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20110033420
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 13, 2010
    Publication date: February 10, 2011
    Inventors: Yonghua Gai, Yat Sun Or, Guoqiang Wang
  • ?-(N-sulfonamido)acetamide derivatives as ?-amyloid inhibitors
    Patent number: 7786122
    Abstract: There is provided a series of novel ?-(N-sulfonamido)acetamide compounds of the Formula (I) wherein R, R1, R2 and R3 are defined herein, which are inhibitors of ?-amyloid peptide (?-AP) production and are useful in the treatment of Alzheimer's Disease and other conditions affected by anti-amyloid activity.
    Type: Grant
    Filed: October 11, 2007
    Date of Patent: August 31, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael F. Parker, Katharine E. McElhone, Robert A. Mate, Joanne J. Bronson, Yonghua Gai, Carl P. Bergstrom, Lawrence R. Marcin, John E. Macor
  • Macrocyclic hepatitis C serine protease inhibitors
    Publication number: 20100144608
    Abstract: The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
    Type: Application
    Filed: September 10, 2009
    Publication date: June 10, 2010
    Inventors: Yiyin Ku, Keith F. McDaniel, Hui-Ju Chen, Jason P. Shanley, Dale J. Kempf, David J. Grampovnik, Ying Sun, Dong Liu, Yonghua Gai, Yat Sun Or, Seble H. Wagaw, Ken Engstrom, Tim Grieme, Ahmad Sheikh, Jianzhang Mei
  • Arylalkoxyl hepatitis C virus protease inhibitors
    Patent number: 7687459
    Abstract: The present invention discloses compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the present invention.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: March 30, 2010
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Yonghua Gai, Yat Sun Or, Zhe Wang
  • QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20100003214
    Abstract: The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: November 14, 2008
    Publication date: January 7, 2010
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang
  • Quinoxalinyl tripeptide hepatitis C virus inhibitors
    Patent number: 7635683
    Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 4, 2006
    Date of Patent: December 22, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yonghua Gai, Deqiang Niu, Yat Sun Or, Zhe Wang
  • DIFLUOROMETHYL-CONTAINING MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20090274657
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: April 30, 2009
    Publication date: November 5, 2009
    Inventors: Yonghua Gai, Dong Liu, Joel D. Moore, Yat Sun Or, Zhe Wang
  • Acylaminoheteroaryl hepatitis C virus protease inhibitors
    Patent number: 7605126
    Abstract: The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: October 20, 2009
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Deqiang Niu, Joel D. Moore, Dong Liu, Yonghua Gai, Zhigang Chen, Yat Sun Or, Zhe Wang
  • FLUORINATED MACROCYCLIC COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
    Publication number: 20090238794
    Abstract: The present invention discloses compounds of formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: March 19, 2009
    Publication date: September 24, 2009
    Inventors: Yonghua Gai, Yat Sun Or, Zhe Wang